SuperworthProcessa Pharmaceuticals revenue PCSA
Sales by quarter and over the last twelve months, from 2012.
- Last 12 months, to Sep 30, 2016
- n/m
- a quarter missing
- Latest quarter, Q3 FY16
- $0
- −100% on a year earlier
- Fiscal year 2014
- $200.3K
- −36% on the year before
Processa Pharmaceuticals' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q3 FY16, it was $0, down 100% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2014 | $200.3K | −36% |
| FY2013 | $312.5K | +63% |
| FY2012 | $192.1K | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY16 | $0 | −100% | n/a | |
| Q2 FY16 | $0 | −100% | n/a | |
| Q1 FY16 | $5K | −87% | n/a | |
| Q3 FY15 | $58.2K | +11% | $130.4K | |
| Q2 FY15 | $20K | −82% | $124.8K | |
| Q1 FY15 | $37.8K | +85% | $217.6K | |
| Q4 FY14 | $14.4K | −79% | $200.3K | |
| Q3 FY14 | $52.6K | −58% | $256K | |
| Q2 FY14 | $112.8K | +16% | $329.3K | |
| Q1 FY14 | $20.4K | +6% | $313.7K | |
| Q4 FY13 | $70.1K | +123% | $312.5K | |
| Q3 FY13 | $125.9K | +157% | $273.8K |
Against its peers
Companies in Healthcare nearest Processa Pharmaceuticals' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| PCSAProcessa Pharmaceuticals | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $2.8M | +40% a year |
| EDUCEducational Development | $20M | −32% a year |
| GTIMGood Times Restaurants | $135.1M | −6% a year |
| MDRRMedalist Diversified | $9.6M | −1% a year |
| BCGBinah Capital | $191.9M | +8% a year |
| VIPVulcan Infrastructure & Power | $50.9M | −14% a year |
| MXCMexco Energy | $6.7M | −9% a year |
| CKXCKX Lands | $693.4K | −17% a year |
| MSGMMotorsport Games | $14.5M | +79% a year |
| ATCHAtlasClear | $20.1M | +85% a year |
| Peer median | $17.3M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Processa Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.